gliflozin

Gliflozin, also known as canagliflozin, is a medication used to treat type 2 diabetes and chronic kidney disease. It belongs to a class of drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors, which work by preventing the kidneys from reabsorbing glucose back into the bloodstream.

Gliflozin was first approved for use in Japan in 2013 and has since been approved in numerous countries around the world, including the United States, Europe, and Australia. It is typically prescribed alone or in combination with other medications, such as metformin or pioglitazone, to regulate blood sugar levels.

The mechanism of action of gliflozin involves the inhibition of SGLT2, a protein in the kidneys that is responsible for the reabsorption of glucose. By inhibiting this protein, gliflozin allows the kidneys to excrete excess glucose in the urine, reducing blood sugar levels. Gliflozin has also been shown to have beneficial effects on blood pressure and weight loss, as well as a reduced risk of kidney damage and cardiovascular events.

Common side effects of gliflozin include increased urination, genital fungal infections, and thirst. In addition, gliflozin has been associated with an increased risk of diabetic ketoacidosis, a potentially life-threatening condition that occurs when the body produces high levels of ketones. Patients taking gliflozin should be monitored regularly for signs of this condition. Overall, gliflozin is a prescribed medication for individuals with type 2 diabetes and chronic kidney disease, offering a new treatment option for managing blood sugar levels.